000179862 001__ 179862
000179862 005__ 20240229145556.0
000179862 0247_ $$2doi$$a10.3389/fonc.2022.853495
000179862 0247_ $$2pmid$$apmid:35530308
000179862 0247_ $$2pmc$$apmc:PMC9069208
000179862 0247_ $$2altmetric$$aaltmetric:127015910
000179862 037__ $$aDKFZ-2022-00936
000179862 041__ $$aEnglish
000179862 082__ $$a610
000179862 1001_ $$0P:(DE-He78)b46c11295b94a94d71c0d912fc1b858f$$aLongarino, Friderike$$b0$$eFirst author$$udkfz
000179862 245__ $$aPotential of a Second-Generation Dual-Layer Spectral CT for Dose Calculation in Particle Therapy Treatment Planning.
000179862 260__ $$aLausanne$$bFrontiers Media$$c2022
000179862 3367_ $$2DRIVER$$aarticle
000179862 3367_ $$2DataCite$$aOutput Types/Journal article
000179862 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1652273775_11191
000179862 3367_ $$2BibTeX$$aARTICLE
000179862 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000179862 3367_ $$00$$2EndNote$$aJournal Article
000179862 500__ $$a#EA:E050#
000179862 520__ $$aIn particle therapy treatment planning, dose calculation is conducted using patient-specific maps of tissue ion stopping power ratio (SPR) to predict beam ranges. Improving patient-specific SPR prediction is therefore essential for accurate dose calculation. In this study, we investigated the use of the Spectral CT 7500, a second-generation dual-layer spectral computed tomography (DLCT) system, as an alternative to conventional single-energy CT (SECT) for patient-specific SPR prediction. This dual-energy CT (DECT)-based method allows for the direct prediction of SPR from quantitative measurements of relative electron density and effective atomic number using the Bethe equation, whereas the conventional SECT-based method consists of indirect image data-based prediction through the conversion of calibrated CT numbers to SPR. The performance of the Spectral CT 7500 in particle therapy treatment planning was characterized by conducting a thorough analysis of its SPR prediction accuracy for both tissue-equivalent materials and common non-tissue implant materials. In both instances, DLCT was found to reduce uncertainty in SPR predictions compared to SECT. Mean deviations of 0.7% and 1.6% from measured SPR values were found for DLCT- and SECT-based predictions, respectively, in tissue-equivalent materials. Furthermore, end-to-end analyses of DLCT-based treatment planning were performed for proton, helium, and carbon ion therapies with anthropomorphic head and pelvic phantoms. 3D gamma analysis was performed with ionization chamber array measurements as the reference. DLCT-predicted dose distributions revealed higher passing rates compared to SECT-predicted dose distributions. In the DLCT-based treatment plans, measured distal-edge evaluation layers were within 1 mm of their predicted positions, demonstrating the accuracy of DLCT-based particle range prediction. This study demonstrated that the use of the Spectral CT 7500 in particle therapy treatment planning may lead to better agreement between planned and delivered dose compared to current clinical SECT systems.
000179862 536__ $$0G:(DE-HGF)POF4-315$$a315 - Bildgebung und Radioonkologie (POF4-315)$$cPOF4-315$$fPOF IV$$x0
000179862 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000179862 650_7 $$2Other$$aSpectral CT 7500
000179862 650_7 $$2Other$$adual-layer spectral CT
000179862 650_7 $$2Other$$aparticle therapy
000179862 650_7 $$2Other$$arange uncertainty
000179862 650_7 $$2Other$$astopping power ratio
000179862 650_7 $$2Other$$atreatment planning
000179862 7001_ $$0P:(DE-He78)8bb62af752b9a1a2ef574e94d52da6a1$$aKowalewski, Antonia$$b1$$udkfz
000179862 7001_ $$aTessonnier, Thomas$$b2
000179862 7001_ $$0P:(DE-HGF)0$$aMein, Stewart$$b3
000179862 7001_ $$aAckermann, Benjamin$$b4
000179862 7001_ $$0P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDebus, Jürgen$$b5$$udkfz
000179862 7001_ $$aMairani, Andrea$$b6
000179862 7001_ $$aStiller, Wolfram$$b7
000179862 773__ $$0PERI:(DE-600)2649216-7$$a10.3389/fonc.2022.853495$$gVol. 12, p. 853495$$p853495$$tFrontiers in oncology$$v12$$x2234-943X$$y2022
000179862 909CO $$ooai:inrepo02.dkfz.de:179862$$pVDB
000179862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)b46c11295b94a94d71c0d912fc1b858f$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000179862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8bb62af752b9a1a2ef574e94d52da6a1$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000179862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000179862 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)8714da4e45acfa36ce87c291443a9218$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000179862 9131_ $$0G:(DE-HGF)POF4-315$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vBildgebung und Radioonkologie$$x0
000179862 9141_ $$y2022
000179862 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2021-01-27
000179862 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-27
000179862 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-27
000179862 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2021-01-27
000179862 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2021-01-27
000179862 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bFRONT ONCOL : 2021$$d2022-11-08
000179862 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000179862 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000179862 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2021-05-11T13:25:45Z
000179862 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2021-05-11T13:25:45Z
000179862 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2021-05-11T13:25:45Z
000179862 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000179862 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000179862 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2022-11-08
000179862 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bFRONT ONCOL : 2021$$d2022-11-08
000179862 9201_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000179862 9201_ $$0I:(DE-He78)E210-20160331$$kE210$$lE210 Translationale Radioonkologie$$x1
000179862 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000179862 9200_ $$0I:(DE-He78)E050-20160331$$kE050$$lE050 KKE Strahlentherapie$$x0
000179862 980__ $$ajournal
000179862 980__ $$aVDB
000179862 980__ $$aI:(DE-He78)E050-20160331
000179862 980__ $$aI:(DE-He78)E210-20160331
000179862 980__ $$aI:(DE-He78)HD01-20160331
000179862 980__ $$aUNRESTRICTED